Get the Stockscreener App
20.06
5.33%
-1.13
After Hours:
20.00
-0.06
-0.30%
Tonix Pharmaceuticals Holding Corp stock is traded at $20.06, with a volume of 1.02M.
It is down -5.33% in the last 24 hours and down -29.88% over the past month.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.
See More
Previous Close:
$21.19
Open:
$20.63
24h Volume:
1.02M
Relative Volume:
0.69
Market Cap:
$175.84M
Revenue:
-
Net Income/Loss:
$-121.02M
P/E Ratio:
-1.7815
EPS:
-11.26
Net Cash Flow:
$-114.09M
1W Performance:
-17.18%
1M Performance:
-29.88%
6M Performance:
+18.84%
1Y Performance:
+35.91%
1-Day Range:
$19.92
$20.69
1-Week Range:
$19.92
$24.49
52-Week Range:
$7.31
$130.00
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Name
Tonix Pharmaceuticals Holding Corp
Sector
Industry
Phone
212-980-9155
Address
26 MAIN STREET, SUITE 101, CHATHAM, NY
Compare TNXP with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
20.06 | 185.75M | 0 | -121.02M | -114.09M | -11.26 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-18-22 | Initiated | Noble Capital Markets | Outperform |
| Apr-18-19 | Upgrade | ROTH Capital | Neutral → Buy |
| Aug-18-17 | Upgrade | ROTH Capital | Neutral → Buy |
| Sep-07-16 | Downgrade | ROTH Capital | Buy → Neutral |
| Feb-17-16 | Reiterated | Oppenheimer | Outperform |
| Nov-04-15 | Initiated | Cantor Fitzgerald | Buy |
| Jun-12-15 | Initiated | Oppenheimer | Outperform |
| Feb-17-15 | Reiterated | ROTH Capital | Buy |
| Sep-29-14 | Reiterated | ROTH Capital | Buy |
View All
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Latest News
How to recover losses in Tonix Pharmaceuticals Holding Corp. stock2025 Support & Resistance & Low Risk High Reward Trade Ideas - newser.com
Using portfolio simulators with Tonix Pharmaceuticals Holding Corp. includedJuly 2025 Fed Impact & Low Drawdown Investment Strategies - newser.com
Can Tonix Pharmaceuticals Holding Corp. recover in the next quarterJuly 2025 Opening Moves & Technical Buy Zone Confirmations - newser.com
Tonix Pharmaceuticals Holding Corp. stock retracement – recovery analysisWeekly Trade Review & AI Forecast Swing Trade Picks - newser.com
Backtesting results for Tonix Pharmaceuticals Holding Corp. trading strategiesWeekly Market Outlook & Daily Profit Focused Screening - newser.com
Analyzing Tonix Pharmaceuticals Holding Corp. with risk reward ratio chartsJuly 2025 Breakouts & Smart Money Movement Tracker - newser.com
Tonix Pharmaceuticals Holding Corp. stock daily chart insightsJuly 2025 PostEarnings & High Return Trade Opportunity Guides - newser.com
Weiss Ratings Reaffirms Sell (E+) Rating for Tonix Pharmaceuticals (NASDAQ:TNXP) - MarketBeat
Fibromyalgia Market Expected to Gain Momentum Through 2034, According to DelveInsight | UCB Pharma, Eli Lilly and Company, Merck, Aptinyx, Astellas Pharma, Tonix Pharma, UCB Biopharma SRL, GSK - Barchart.com
Fibromyalgia Market Expected to Gain Momentum Through 2034, - openPR.com
Tonix Pharmaceuticals to Present and Participate in Panel Discussion at World Vaccine Congress, Europe 2025 - The Manila Times
Single‑Dose TNX-801 Mpox Vaccine: Tonix to Present Safety & Durability Data at World Vaccine Congress Europe - Stock Titan
Detecting price anomalies in Tonix Pharmaceuticals Holding Corp. with AI2025 Sector Review & Real-Time Buy Signal Notifications - newser.com
Automated trading signals detected on Tonix Pharmaceuticals Holding Corp.Earnings Miss & Daily Volume Surge Trade Alerts - newser.com
What analysts say about Tonix Pharmaceuticals Holding Corp stockResistance Breakout Alerts & Affordable Growth Strategies - earlytimes.in
Tonix Pharmaceuticals (TNXP) Plans New Phase 2 Trials for Key Tr - GuruFocus
Tonix Pharma Plans Phase 2 Trial for 2026 - TipRanks
Tonix to advance cyclobenzaprine into phase 2 for depression - Seeking Alpha
How Tonix Pharmaceuticals Holding Corp. stock performs after earningsPortfolio Growth Summary & Risk Managed Investment Signals - newser.com
Is Tonix Pharmaceuticals Holding Corp. trending in predictive chart models2025 Investor Takeaways & Daily Price Action Insights - newser.com
Custom watchlist performance reports with Tonix Pharmaceuticals Holding Corp.2025 Valuation Update & Safe Capital Growth Tips - newser.com
What data driven models say about Tonix Pharmaceuticals Holding Corp.’s futureWeekly Trend Recap & Free Weekly Watchlist of Top Performers - newser.com
Tonix Pharmaceuticals (NASDAQ:TNXP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Tonix Pharmaceuticals advances TNX-2900 into Phase 2 trial for Prader-Willi Syndrome - Proactive financial news
Tonix Pharma Appoints New Head of Market Access - MSN
Tonix Pharmaceuticals Further Strengthens Commercial Leadership Team with Appointment of Ganesh Kamath as Head of Market Access - Sahm
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access By Investing.com - Investing.com Nigeria
Acadia’s Prader-Willi miss gives Tonix a chance at the market - BioCentury
Tonix Pharmaceuticals Advances TNX-2900 for Prader-Willi Syndrome to Phase 2 Clinical Trial - citybuzz
Tonix Pharmaceuticals Further Strengthens Commercial - GlobeNewswire
Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access - citybiz
Will the first fibromyalgia drug in 15 years deliver a breakthrough in pain? - PharmaVoice
Tonix Pharmaceuticals appoints Ganesh Kamath as head of market access - Investing.com
Tonix Pharmaceuticals Appoints Ganesh Kamath as Head of Market Access Ahead of Tonmya™ Launch for Fibromyalgia Treatment - Quiver Quantitative
First New Fibromyalgia Treatment in 15 Years: Tonix Pharma Builds Launch Team for FDA-Approved Tonmya - Stock Titan
Tonix to begin phase 2 trial of PWS treatment with orphan status - Investing.com Nigeria
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):